SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Cindy Ke Zhou, David P. Check, Joannie Lortet-Tieulent, Mathieu Laversanne, Ahmedin Jemal, Jacques Ferlay, Freddie Bray, Michael B. Cook, Susan S. Devesa, Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group, International Journal of Cancer, 2016, 138, 6
  2. 2
    J. Dickinson, A. Shane, M. Tonelli, S. C. Gorber, M. Joffres, H. Singh, N. Bell, Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening, CMAJ Open, 2016, 4, 1, E73

    CrossRef

  3. 3
    Randi V. Karlsen, Signe B. Larsen, Jane Christensen, Klaus Brasso, Søren Friis, Anne Tjønneland, Susanne Oksbjerg Dalton, PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study, Acta Oncologica, 2013, 52, 8, 1609

    CrossRef

  4. 4
    Richard M. Hoffman, Screening for Prostate Cancer, New England Journal of Medicine, 2011, 365, 21, 2013

    CrossRef

  5. 5
    Richard M Hoffman, Anthony Y Smith, What we have learned from randomized trials of prostate cancer screening, Asian Journal of Andrology, 2011, 13, 3, 369

    CrossRef

  6. 6
    Nancie Petrucelli, Mary B Daly, Gerald L Feldman, Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2, Genetics in Medicine, 2010, 12, 5, 245

    CrossRef

  7. 7
    David J. Mener, Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature, IUBMB Life, 2010, 62, 8
  8. 8
    Ling Zhang, Shan Wu, Li-Rong Guo, Xue-Jian Zhao, Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China, Asian Journal of Andrology, 2009, 11, 1, 9

    CrossRef

  9. 9
    Konstantinos Stamatiou, Andreas Skolarikos, Ioannis Heretis, Vaios Papadimitriou, Alevizos Alevizos, Georgios Ilias, Vasilissa Karanasiou, Anargiros Mariolis, Frank Sofras, Does educational printed material manage to change compliance with prostate cancer screening?, World Journal of Urology, 2008, 26, 4, 365

    CrossRef

  10. 10
    Ewa Kuligowska, James Stinchon, Diagnostic Ultrasound, Second Edition, 2008,

    CrossRef

  11. 11
    Judd W. Moul, A discussion of general prostate cancer screening versus targeted diagnosis in younger men, Current Prostate Reports, 2005, 3, 3, 99

    CrossRef

  12. 12
    Andreas P. Berger, Martina Deibl, Hannes Steiner, Jasmin Bektic, Alexandre Pelzer, Robert Spranger, Helmut Klocker, Georg Bartsch, Wolfgang Horninger, Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk, The Prostate, 2005, 64, 3
  13. 13
    X Ni, W Zhang, K-C Huang, Y Wang, S-K Ng, S C Mok, R S Berkowitz, S-W Ng, Characterisation of human kallikrein 6/protease M expression in ovarian cancer, British Journal of Cancer, 2004,

    CrossRef

  14. 14
    Javier Hernandez, Ian M Thompson, Diagnosis and treatment of prostate cancer, Medical Clinics of North America, 2004, 88, 2, 267

    CrossRef

  15. 15
    J.a Hyeon Ku, Min Eui Kim, Nam Kyu Lee, Young H.o Park, Jae Ouk Ahn, Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men, Urology, 2003, 61, 1, 132

    CrossRef

  16. 16
    Judd W. Moul, Population Screening for Prostate Cancer and Emerging Concepts for Young Men, Clinical Prostate Cancer, 2003, 2, 2, 87

    CrossRef

  17. 17
    J. Hugosson, G. Aus, S. Bergdahl, P. Fernlund, R. Frösing, P. Lodding, C.-G. Pihl, H. Lilja, Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden, BJU International, 2003, 92,
  18. 18
    Robert G. Uzzo, Deborah Watkins-Bruner, Eric M. Horwitz, Andre Konski, Alan Pollack, Paul F. Engstrom, Vladimir Kolenko, Prostate Cancer, 2003,

    CrossRef

  19. 19
    Judd W. Moul, Prostate Cancer, 2003,

    CrossRef

  20. 20
    Richard C. Wender, Robert Smith, Diane Harper, Cancer screening, Primary Care: Clinics in Office Practice, 2002, 29, 3, 697

    CrossRef

  21. 21
    Ja Hyeon Ku, Jae Ouk Ahn, Chang Ho Lee, Nam Kyu Lee, Young Ho Park, Seok Soo Byun, Cheol Kwak, Sang Eun Lee, Distribution of serum prostate-specific antigen in healthy korean men: influence of ethnicity, Urology, 2002, 60, 3, 475

    CrossRef

  22. 22
    John M Fitzpatrick, George Blackledge, Don Newling, PSA—Promoter of Stress and Anxiety or Providentially-Sent Antigen?, European Urology Supplements, 2002, 1, 7, 10

    CrossRef

  23. 23
    Kyle K. Yu, Steven C. Eberhardt, Hedvig Hricak, Oncologic Imaging, 2002,

    CrossRef

  24. 24
    M.J. Duffy, Clinical Uses of Tumor Markers: A Critical Review, Critical Reviews in Clinical Laboratory Sciences, 2001, 38, 3, 225

    CrossRef

  25. 25
    Ray M. Merrill, Demographics and Health-Related Factors of Men Receiving Prostate-Specific Antigen Screening in Utah, Preventive Medicine, 2001, 33, 6, 646

    CrossRef

  26. 26
    S Egawa, Detection of prostate cancer by prostate-specific antigen, Biomedicine & Pharmacotherapy, 2001, 55, 3, 130

    CrossRef

  27. 27
    Martine Barette, Françoise Renard, Alexandre Peltier, Roland van Velthoven, Françoise Huet, André R Grivegnée, Philippe Autier, Evaluation of a low-invasive strategy for prostate cancer screening with prostate-specific antigen, Urology, 2001, 57, 4, 712

    CrossRef

  28. 28
    R. F. Hoedemaeker, T. H. van der Kwast, R. Boer, H. J. de Koning, M. Roobol, A. N. Vis, F. H. Schroder, Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval, JNCI Journal of the National Cancer Institute, 2001, 93, 15, 1153

    CrossRef

  29. 29
    John D. Voss, Joel M. Schectman, Prostate Cancer Screening Practices and Beliefs, Journal of General Internal Medicine, 2001, 16, 12
  30. 30
    André N. Vis, Robert F. Hoedemaeker, Monique Roobol, Theo H. van der Kwast, Fritz H. Schröder, Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0–3.9 ng/ml), The Prostate, 2001, 47, 4
  31. 31
    Outpatient Management of HIV Infection, Third Edition, 2001,

    CrossRef

  32. 32
    Sozos J. Fasouliotis, Joseph G. Schenker, BRCA1 and BRCA2 Gene Mutations: Decision-Making Dilemmas Concerning Testing and Management, Obstetrical & Gynecological Survey, 2000, 55, 6, 373

    CrossRef

  33. 33
    Michael A. Silverman, Uzma Zaidi, Scott Barnett, Carlos Robles, Vikas Khurana, Howard Manten, David Barnes, Lucy Chua, Bernard A. Roos, CANCER SCREENING IN THE ELDERLY POPULATION, Hematology/Oncology Clinics of North America, 2000, 14, 1, 89

    CrossRef

  34. 34
    J. Jaime Caro, Wendy S. Klittich, Gary Strauss, Could chest X-ray screening for lung cancer be cost-effective?, Cancer, 2000, 89, S11
  35. 35
    D.K. Agarwal, A.J. Costello, J. Peters, K. Sikaris, H. Crowe, Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia, BJU International, 2000, 85, 6
  36. 36
    Kyle K. Yu, Hedvig Hricak, IMAGING PROSTATE CANCER, Radiologic Clinics of North America, 2000, 38, 1, 59

    CrossRef

  37. 37
    Peter Clarke, Part II. Prostate cancer screening, Disease-a-Month, 2000, 46, 6, 382

    CrossRef

  38. 38
    Deborah Watkins Bruner, Mary Pickett, Angela Joseph, Virginia Burggraf, Prostate Cancer Elder Alert, Journal of Gerontological Nursing, 2000, 26, 1, 6

    CrossRef

  39. 39
    David M Preston, Lynn I Levin, Debra J Jacobson, Steven J Jacobsen, Mark Rubertone, Eric Holmes, Gerald P Murphy, Judd W Moul, Prostate-specific antigen levels in young white and black men 20 to 45 years old, Urology, 2000, 56, 5, 812

    CrossRef

  40. 40
    Michael K. Brawer, Screening for prostate cancer, Seminars in Surgical Oncology, 2000, 18, 1
  41. 41
    I.C. Bennett, M. Gattas, B.T. Teh, The management of familial breast cancer, The Breast, 2000, 9, 5, 247

    CrossRef

  42. 42
    Steven R. Potter, H. Ballentine Carter, The role of prostate-specific antigen velocity in prostate cancer early detection, Current Urology Reports, 2000, 1, 1, 15

    CrossRef

  43. 43
    Darrel E. Drachenberg, Treatment of prostate cancer: Watchful waiting, radical prostatectomy, and cryoablation, Seminars in Surgical Oncology, 2000, 18, 1
  44. 44
    Richard M. Hoffman, David L. Clanon, Benjamin Littenberg, Joseph J. Frank, John C. Peirce, Using the Free-to-total Prostate-specific Antigen Ratio to Detect Prostate Cancer in Men with Nonspecific Elevations of Prostate-specific Antigen Levels, Journal of General Internal Medicine, 2000, 15, 10
    Direct Link:
  45. 45
    J. Hugosson, G. Aus, C. Becker, S. Carlsson, H. Eriksson, H. Lilja, P. Lodding, G. Tibblin, Would prostate cancer detected by screening withprostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden, BJU International, 2000, 85, 9
  46. 46
    Ronald E. Myers, Gerald W. Chodak, Thomas A. Wolf, Desiree Y. Burgh, Gene T. McGrory, Sue M. Marcus, Julie A. Diehl, Melissa Williams, Adherence by African American men to prostate cancer education and early detection, Cancer, 1999, 86, 1
  47. 47
    ROSEBUD O. ROBERTS, ERIK J. BERGSTRALH, SLAVICA K. KATUSIC, MICHAEL M. LIEBER, STEVEN J. JACOBSEN, DECLINE IN PROSTATE CANCER MORTALITY FROM 1980 TO 1997, AND AN UPDATE ON INCIDENCE TRENDS IN OLMSTED COUNTY, MINNESOTA, The Journal of Urology, 1999, 161, 2, 529

    CrossRef

  48. 48
    ROSEBUD O. ROBERTS, ERIK J. BERGSTRALH, SLAVICA K. KATUSIC, MICHAEL M. LIEBER, STEVEN J. JACOBSEN, DECLINE IN PROSTATE CANCER MORTALITY FROM 1980 TO 1997, AND AN UPDATE ON INCIDENCE TRENDS IN OLMSTED COUNTY, MINNESOTA, The Journal of Urology, 1999, 529

    CrossRef

  49. 49
    SUSAN L. ZWEIZIG, Office Screening for Gynecologic Cancer, Clinical Obstetrics and Gynecology, 1999, 42, 2, 267

    CrossRef

  50. 50
    Lynn E. Hahnfeld, Timothy D. Moon, PROSTATE CANCER, Medical Clinics of North America, 1999, 83, 5, 1231

    CrossRef

  51. 51
    Paul A. Godley, Prostate Cancer Screening: Promise and Peril-A Review, Cancer Detection <html_ent glyph="@amp;" ascii="&amp;"/> Prevention, 1999, 23, 4, 316

    CrossRef

  52. 52
    Robert C. Burack, David P. Wood, SCREENING FOR PROSTATE CANCER, Medical Clinics of North America, 1999, 83, 6, 1423

    CrossRef

  53. 53
    Steven H. Woolf, MD, MPH, Stephen F. Rothemich, MD, SCREENING FOR PROSTATE CANCER: The Roles of Science, Policy, and Opinion in Determining What is Best for Patients, Annual Review of Medicine, 1999, 50, 1, 207

    CrossRef

  54. 54
    Seth A Eisen, Brian Waterman, Celette Sugg Skinner, Jeffrey F Scherrer, James C Romeis, Kathleen Bucholz, Andrew Heath, Jack Goldberg, Michael J Lyons, Ming T Tsuang, William R True, Sociodemographic and health status characteristics associated with prostate cancer screening in a national cohort of middle-aged male veterans, Urology, 1999, 53, 3, 516

    CrossRef

  55. 55
    Schwartz, Faught, Jezior, The effect of colonoscopy on serum prostate specific antigen levels, BJU International, 1999, 84, 3
  56. 56
    Ian C. Bennett, Michael Gattas, Bin Tean Teh, THE GENETIC BASIS OF BREAST CANCER AND ITS CLINICAL IMPLICATIONS, Australian and New Zealand Journal of Surgery, 1999, 69, 2
  57. 57
    G. Burdea, G. Patounakis, V. Popescu, R.E. Weiss, Virtual reality-based training for the diagnosis of prostate cancer, IEEE Transactions on Biomedical Engineering, 1999, 46, 10, 1253

    CrossRef

  58. 58
    Robert M. Nakamura, Current status and future directions in standardization of prostate-specific antigen immunoassay, Urology, 1998, 51, 5, 83

    CrossRef

  59. 59
    JamesB Meigs, MichaelJ Barry, Edward Giovannucci, EricB Rimm, MeirJ Stampfer, Ichiro Kawachi, High Rates of Prostate-specific Antigen Testing in Men with Evidence of Benign Prostatic Hyperplasia, The American Journal of Medicine, 1998, 104, 6, 517

    CrossRef

  60. 60
    A. Farkas, D. Schneider, M. Perrotti, K.B. Cummings, W.S. Ward, National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening, Urology, 1998, 52, 3, 444

    CrossRef

  61. 61
    Judith K. Zemencuk, John W. Feightner, Rodney A. Hayward, Kimberly A. Skarupski, Steven J. Katz, Patients’ Desires and Expectations for Medical Care in Primary Care Clinics, Journal of General Internal Medicine, 1998, 13, 4
    Direct Link:
  62. 62
    Sally Weinrich, Diane Holdford, Marlyn Boyd, Dana Creanga, Kay Cover, Alonzo Johnson, Marilyn Frank-Stromborg, Martin Weinrich, Prostate Cancer Education in African American Churches, Public Health Nursing, 1998, 15, 3
  63. 63
    Floyd J Fowler, Lin Bin, Mary McNaughton Collins, Richard G Roberts, Joseph E Oesterling, John H Wasson, Michael J Barry, Prostate Cancer Screening and Beliefs about Treatment Efficacy: A National Survey of Primary Care Physicians and Urologists, The American Journal of Medicine, 1998, 104, 6, 526

    CrossRef

  64. 64
    Peter S Bunting, Nelson Chong, Eric J Holowaty, Vivek Goel, Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer, Clinical Biochemistry, 1998, 31, 6, 501

    CrossRef

  65. 65
    Richard M. Hoffman, Philip Blume, Frank Gilliland, Prostate-Specific Antigen Testing Practices and Outcomes, Journal of General Internal Medicine, 1998, 13, 2
    Direct Link:
  66. 66
    Arnold L. Potosky, Nancy Breen, Barry I. Graubard, P. Ellen Parsons, The Association Between Health Care Coverage and the Use of Cancer Screening Tests, Medical Care, 1998, 36, 3, 257

    CrossRef

  67. 67
    Jim Gottesman, Neil Baum, Common urologic disorders, Postgraduate Medicine, 1997, 102, 2, 235

    CrossRef

  68. 68
    Michael K. Brawer, Daniel D. Bankson, Virginia M. Haver, Jason C. Petteway, Comparison of three commercial PSA assays: Results of restandardization of the Ciba Corning method, The Prostate, 1997, 30, 4
  69. 69
    M. Cristine Charlesworth, Charles Y-F Young, George G. Klee, Mohammad S. Saedi, Stephen D. Mikolajczyk, Judith A. Finlay, Donald J. Tindall, Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels, Urology, 1997, 49, 3, 487

    CrossRef

  70. 70
    R.G. NIXON, M.K. BRAWER, Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges, British Journal of Urology, 1997, 79, S1
  71. 71
    M.O. Korhonen, J.P. Symons, B.M. Hyde, J.P. Rowan, W.H. Wilborn, Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study), American Journal of Obstetrics and Gynecology, 1997, 176, 2, 377

    CrossRef

  72. 72
    Gary M. Strauss, Measuring Effectiveness of Lung Cancer Screening, Chest, 1997, 112, 4, 216S

    CrossRef

  73. 73
    Russell M. Freid, Nina S. Davis, Gary H. Weiss, PROSTATE CANCER SCREENING AND MANAGEMENT, Medical Clinics of North America, 1997, 81, 3, 801

    CrossRef

  74. 74
    Martha S. Tingen, Sally P. Weinrich, Marlyn D. Boyd, Martin C. Weinrich, Prostate Cancer Screening: Predictors of Participation, Journal of the American Academy of Nurse Practitioners, 1997, 9, 12
  75. 75
    W.M. Garraway, F.E. Alexander, Prostate disease: epidemiology, natural history and demographic shifts, British Journal of Urology, 1997, 79, S2
  76. 76
    Ted O. Morgan, Steven J. Jacobsen, William F. McCarthy, Debra J. Jacobson, David G. McLeod, Judd W. Moul, Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men, New England Journal of Medicine, 1996, 335, 5, 304

    CrossRef

  77. 77
    Theresa Widrich, Linda D. Bradley, Allison R. Mitchinson, Robert L. Collins, Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium, American Journal of Obstetrics and Gynecology, 1996, 174, 4, 1327

    CrossRef

  78. 78
    Thomas M. Pisansky, Horst Zincke, Vera J. Suman, David G. Bostwick, John D. Earle, Joseph E. Oesterling, Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens, International Journal of Radiation Oncology*Biology*Physics, 1996, 34, 1, 33

    CrossRef

  79. 79
    Louis L. Pisters, Editorial, The Journal of Urology, 1996, 1678

    CrossRef

  80. 80
    Ronald E. Myers, Thomas A. Wolf, Linda McKee, Gene McGrory, Desiree Y. Burgh, Gregory Nelson, Gail A. Nelson, Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia, Cancer, 1996, 78, 3
  81. 81
    M.-E. Toubert, J. Guillet, M. Chiron, P. Meria, C. Role, M.-H. Schlageter, H. Francois, C. Borschneck, F. Nivelon, F. Desgrandchamps, D. Rastel, O. Cussenot, P. Teillac, A. Le Duc, Y. Najean, Percentage of free serum prostate-specific antigen: A new tool in the early diagnosis of prostatic cancer, European Journal of Cancer, 1996, 32, 12, 2088

    CrossRef

  82. 82
    D. BRUCE SODEE, RIDGELY CONANT, MARSHALL CHALFANT, STEFAN MIRON, ERIC KLEIN, ROBERT BAHNSON, J. PATRICK SPIRNAK, BRUCE CARLIN, ERROL M. BELLON, BARBARA ROGERS, Preliminary Imaging Results Using In-111 Labeled CYT-356 (Prostascintst) in the Detection of Recurrent Prostate Cancer, Clinical Nuclear Medicine, 1996, 21, 10, 759

    CrossRef

  83. 83
    Russell M. Hostetler, Ira G. Mandel, Jan Marshburn, PROSTATE CANCER SCREENING, Medical Clinics of North America, 1996, 80, 1, 83

    CrossRef

  84. 84
    B Chauvet, T Jacob, JL Davin, C Berger, P Vincent, F Reboul, Prostate specific antigen (PSA): impact d'un marqueur sérique sur la prise en charge diagnostique et thérapeutique des cancers de prostate, Bulletin du Cancer/Radiothérapie, 1996, 83, 4, 334

    CrossRef

  85. 85
    Seth E. Lerner, Thomas M. Seay, Michael L. Blute, Erik J. Bergstralh, David Barrett, Horst Zincke, Prostate Specific Antigen Detected Prostate Cancer (Clinical Stage T1C), The Journal of Urology, 1996, 821

    CrossRef

  86. 86
    W. F. Thon, F. Gadban, M. C. Truss, M. Kuczyk, U. Hartmann, U. Jonas, Prostate-specific antigen density — a reliable parameter for the detection of prostate cancer?, World Journal of Urology, 1996, 14, 1, 53

    CrossRef

  87. 87
    P. Savage, J. Waxman, PSA and prostate cancer diagnosis, European Journal of Cancer, 1996, 32, 7, 1097

    CrossRef

  88. 88
    Ann Barry Flood, John E. Wennberg, Robert F. Nease, Floyd J. Fowler, Jiao Ding, Lynda M. Hynes, The importance of patient preference in the decision to screen for prostate cancer, Journal of General Internal Medicine, 1996, 11, 6, 342

    CrossRef

  89. 89
    Curtis J. Mettlin, Gerald P. Murphy, Reginald Ho, Herman R. Menck, The National Cancer Data Base report on longitudinal observations on prostate cancer, Cancer, 1996, 77, 10
  90. 90
    Curtis Mettlin, Gerald P. Murphy, Richard J. Babaian, Arthur Chesley, Robert A. Kane, Peter J. Littrup, Fatoullah K. Mostofi, Paul S. Ray, Allen M. Shanberg, Ants Toi, The results of a five-year early prostate cancer detection intervention, Cancer, 1996, 77, 1
  91. 91
    Alan W. Partin, H. Ballentine Carter, THE USE OF PROSTATE-SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS OF LOCALIZED PROSTATE CANCER, Urologic Clinics of North America, 1996, 23, 4, 531

    CrossRef

  92. 92
    Martin Gleave, Mark Bandyk, Leland Chung, Some Aspects of Oncology, 1996,

    CrossRef

  93. 93
    CURTIS METTLIN, Changes in Early Detection of Prostate Cancer in the United States, Annals of the New York Academy of Sciences, 1995, 768, 1
  94. 94
    Cheryl T. Lee, Joseph E. Oesterling, Diagnostic markers of prostate cancer: Utility of prostate-specific antigen in diagnosis and staging, Seminars in Surgical Oncology, 1995, 11, 1
  95. 95
    Peter J. Littrup, Allen C. Goodman, Economic considerations of prostate cancer. The role of detection specificity and biopsy reduction, Cancer, 1995, 75, S7
  96. 96
    G.Reza Najem, Marian Rose Catherine Passannante, James D. Foster, Health risk factors and health promoting behavior of medical, dental and nursing students, Journal of Clinical Epidemiology, 1995, 48, 6, 841

    CrossRef

  97. 97
    M.C. PARKINSON, Pre-neoplastic lesions of the prostate, Histopathology, 1995, 27, 4
  98. 98
    Louis J. Denis, Prostate cancer screening and prevention: “realities and hope”, Urology, 1995, 46, 3, 56

    CrossRef

  99. 99
    Steven H. Woolf, Screening for Prostate Cancer with Prostate-Specific Antigen — An Examination of the Evidence, New England Journal of Medicine, 1995, 333, 21, 1401

    CrossRef

  100. 100
    Fritz H. Schröder, Screening, early detection, and treatment of prostate cancer: A European view, Urology, 1995, 46, 3, 62

    CrossRef

  101. 101
    Michael J. Barry, Craig Fleming, Christopher M. Coley, John H. Wasson, Marianne C. Fahs, Joseph E. Oesterling, Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? part I: Framing the debate, Urology, 1995, 46, 1, 2

    CrossRef

  102. 102
    Steven J. Jacobsen, George G. Klee, Hans Lilja, George L. Wright, Joseph E. Oesterling, Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time, Urology, 1995, 45, 3, 447

    CrossRef

  103. 103
    Allan S. Brett, The mammography and prostate-specific antigen controversies, Journal of General Internal Medicine, 1995, 10, 5, 266

    CrossRef

  104. 104
    Curtis J. Mettlin, Gerald P. Murphy, Lamar S. McGinnis, Herman R. Menck, The national cancer data base report on prostate cancer, Cancer, 1995, 76, 6
  105. 105
    Tim Aldrich, Wendy Demark-Wahnefried, Joellen M. Schildkraut, Eugene Lengerich, Elizabeth Conlisk, Curtis Mettlin, Gerald P. Murphy, The national cancer data base report on prostate cancer, Cancer, 1995, 75, 1
  106. 106
    Paul M. O'Neill, Janys E. Fletcher, Christopher G. Stafford, Phelim B. Daniels, Tito Bacarese-Hamilton, Use of an optical biosensor to measure prostate-specific antigen in whole blood, Sensors and Actuators B: Chemical, 1995, 29, 1-3, 79

    CrossRef

  107. 107
    Ronald M. Benoit, Michael J. Naslund, An economic rationale forprostate cancer screening, Urology, 1994, 44, 6, 795

    CrossRef

  108. 108
    G.L. Lu-Yao, E.R. Greenberg, Changes in prostate cancer incidence and treatment in USA, The Lancet, 1994, 343, 8892, 251

    CrossRef

  109. 109
    Steven J. Jacobsen, Hans Lilja, George G. Klee, George L. Wright, Kim Pettersson, Joseph E. Oesterling, Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen, Urology, 1994, 44, 4, 512

    CrossRef

  110. 110
    Frank D. Gilliland, Thomas M. Becker, Charles R. Key, Jonathan M. Samet, Contrasting trends of prostate cancer incidence and mortality in New Mexico's hispanics, non-hispanic whites, American Indians, and blacks, Cancer, 1994, 73, 8
  111. 111
    Robert M. Nakamura, Current and future directions regarding quality assurance and standardization of prostate specific antigen immunoassays, Cancer, 1994, 74, 6
  112. 112
    Anthony B. Miller, Mammography screening guidelines for women 40 to 49 and over 65 years old, Annals of Epidemiology, 1994, 4, 2, 96

    CrossRef

  113. 113
    Peter J. Littrup, Prostate cancer screening. Appropriate choices?, Cancer, 1994, 74, S7
  114. 114
    MICHAEL K. Brawer, Prostate-specific antigen: Critical issues, Urology, 1994, 44, 6, 9

    CrossRef

  115. 115
    HERBERT C. RUCKLE, GEORGE G. KLEE, JOSEPH E. OESTERLING, Prostate-Specific Antigen: Critical Issues for the Practicing Physician, Mayo Clinic Proceedings, 1994, 69, 1, 59

    CrossRef

  116. 116
    T. Ming Chu, Prostate-specific antigen in screening of prostate cancer, Journal of Clinical Laboratory Analysis, 1994, 8, 5
  117. 117
    Ronald A. Morton, Racial differences in adenocarcinoma of the prostate in North American men, Urology, 1994, 44, 5, 637

    CrossRef

  118. 118
    Ronald E. Myers, Thomas A. Wolf, Andrew M. Balshem, Eric A. Ross, Gerald W. Chodak, Receptivity of african-american men to prostate cancer screening, Urology, 1994, 43, 4, 480

    CrossRef

  119. 119
    Curtis Mettlin, Peter J. Littrup, Robert A. Kane, Gerald P. Murphy, Fred Lee, Arthur Chesley, Robert Badalament, Fatollah K. Mostofi, Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change, Cancer, 1994, 74, 5
  120. 120
    A.F Markham, P.L Coletta, P.A Robinson, P Clissold, G.R Taylor, I.M Carr, D.M Meredith, Screening for cancer predisposition, European Journal of Cancer, 1994, 30, 13, 2015

    CrossRef

  121. 121
    Screening for Prostate Cancer, New England Journal of Medicine, 1994, 330, 3, 220

    CrossRef

  122. 122
    Curtis Mettlin, Gerald P. Murphy, Fred Lee, Peter J. Littrup, Arthur Chesley, Richard Babaian, Robert Badalament, Robert A. Kane, F. K. Mostofi, Characteristics of prostate cancers detected in a multimodality early detection program, Cancer, 1993, 72, 5
  123. 123
    Floyd J. Fowler, Michael J. Barry, Grace Lu-yao, Anthony Roman, John Wasson, John E. Wennberg, Patient-re ported complications and follow-up treatment after radical prostatectomy, Urology, 1993, 42, 6, 622

    CrossRef

  124. 124
    Howard C. B. Graves, Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design?, Cancer, 1993, 72, 11